GlassScriptPhysician profile
Gregory A Ennis
NPI 1043255615
$6,742.41
in general payments reported to CMS, 2019-2025
51 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $281 · 2021: $843 · 2022: $985 · 2023: $1,370 · 2024: $1,495 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,083.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $905.04 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $781.76 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $516.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Corium, LLC | $442.69 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $383.31 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $321.70 | 2023-2025 | |
| Gilead Sciences, INC. | $284.10 | 2019-2025 | Epclusa |
| Merck Sharp & Dohme LLC | $198.84 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $198.65 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.50 | 2019-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $166.59 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.88 | 2021-2023 | Trintellix |
| Sumitomo Pharma America, INC. | $159.82 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $157.35 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $141.39 | 2023-2025 | Cologuard Collection Kit |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $139.06 | 2020-2022 | |
| Esperion Therapeutics, INC. | $130.89 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.06 | 2021-2025 | |
| Inari Medical, INC. | $109.85 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Itamar Medical INC | $98.74 | 2022-2023 | Watchpatone |
| Astellas Pharma US INC | $98.61 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $97.52 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $90.47 | 2019-2022 | |
| Dexcom, INC. | $64.27 | 2024-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $60.60 | 2024-2025 | Auvelity |
| Abbott Laboratories | $58.98 | 2023-2025 | Freestyle Libre 3, Penta |
| Teva Pharmaceuticals USA, INC. | $55.20 | 2019-2023 | |
| Clarus Therapeutics INC. | $52.57 | 2021 | |
| Antares Pharma, INC. | $47.82 | 2021-2024 | Xyosted |
| Sunovion Pharmaceuticals INC. | $45.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $45.44 | 2023 | Quviviq |
| Amarin Pharma, INC. | $40.92 | 2020 | |
| Seqirus USA INC | $34.15 | 2025 | Flucelvax, Fluad |
| Ardelyx, INC. | $32.33 | 2024 | Ibsrela |
| Medtronic USA, INC. | $29.32 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $27.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.10 | 2025 | |
| Siemens Medical Solutions USA, INC. | $22.95 | 2022 | |
| Avvisto Therapeutics, LLC | $22.83 | 2025 | Cycloset |
| Sanofi Pasteur INC. | $20.85 | 2025 | |
| Optos, INC. | $20.30 | 2020 | |
| Jazz Pharmaceuticals INC. | $19.30 | 2021 | |
| Corcept Therapeutics | $18.97 | 2025 | Korlym |
| Medtronic, INC. | $18.43 | 2022 | |
| Dynavax Technologies Corporation | $17.14 | 2025 | Heplisav-B |
| Eisai INC. | $16.94 | 2021 | |
| Biogen, INC. | $16.83 | 2021 | |
| Si-Bone, INC. | $16.55 | 2021 | |
| Amgen INC. | $15.03 | 2019 | |
| Allergan, INC. | $12.74 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.